Because treatments which lower plasma IL-6 levels and/or block IL-6 signaling are currently in clinical use for other indications, these agents could be used to test idea that lowering IL-6 may preserve in the integrity of the PV-inhibitory system and prevent associated cognitive deficits. This evidence concerns the gene IL6 and Cognitive impairment.